$FATE
Fate Therapeutics Inc

2018 Q3 Form 10-Q Financial Statement

#000156459018019456 Filed on August 06, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $1.026M $1.027M $1.026M
YoY Change 0.0% 0.1% -0.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.080M $3.820M $2.670M
YoY Change 46.24% 43.07% 18.67%
% of Gross Profit
Research & Development $13.64M $16.82M $7.927M
YoY Change 58.98% 112.14% 16.92%
% of Gross Profit
Depreciation & Amortization $310.0K $280.0K $230.0K
YoY Change 29.17% 21.74% 0.0%
% of Gross Profit
Operating Expenses $17.72M $20.63M $10.60M
YoY Change 55.89% 94.71% 17.33%
Operating Profit -$16.69M -$19.61M -$9.570M
YoY Change 61.43% 104.86%
Interest Expense $429.0K $425.0K -$80.00K
YoY Change 13.49% -631.25% -80.0%
% of Operating Profit
Other Income/Expense, Net -$90.00K -$49.00K
YoY Change
Pretax Income -$16.78M -$19.65M -$9.650M
YoY Change 57.12% 103.63% 14.74%
Income Tax
% Of Pretax Income
Net Earnings -$16.78M -$19.65M -$9.645M
YoY Change 57.08% 103.77% 14.71%
Net Earnings / Revenue -1635.67% -1913.73% -940.06%
Basic Earnings Per Share
Diluted Earnings Per Share -$309.7K -$369.8K -$233.0K
COMMON SHARES
Basic Shares Outstanding 53.42M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $211.2M $78.00M $71.00M
YoY Change 205.2% 9.86% 54.68%
Cash & Equivalents $183.2M $36.16M $31.19M
Short-Term Investments $27.90M $41.90M $40.00M
Other Short-Term Assets $2.200M $2.000M $800.0K
YoY Change 175.0% 150.0% -33.33%
Inventory
Prepaid Expenses
Receivables $500.0K
Other Receivables $0.00
Total Short-Term Assets $213.9M $80.03M $71.90M
YoY Change 205.57% 11.31% 52.65%
LONG-TERM ASSETS
Property, Plant & Equipment $3.800M $2.894M $1.900M
YoY Change 52.0% 52.32% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $100.0K
YoY Change 100.0% 100.0% 0.0%
Total Long-Term Assets $6.100M $3.121M $2.100M
YoY Change 125.93% 48.62% 0.0%
TOTAL ASSETS
Total Short-Term Assets $213.9M $80.03M $71.90M
Total Long-Term Assets $6.100M $3.121M $2.100M
Total Assets $220.0M $83.16M $74.00M
YoY Change 202.61% 12.37% 50.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.200M $3.510M $1.200M
YoY Change 136.36% 192.5% -40.0%
Accrued Expenses $9.600M $8.376M $4.800M
YoY Change 77.78% 74.5% 100.0%
Deferred Revenue $3.250M $1.776M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.300M $2.011M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $22.70M $16.27M $8.100M
YoY Change 134.02% 100.9% -43.36%
LONG-TERM LIABILITIES
Long-Term Debt $11.60M $12.84M $6.700M
YoY Change -21.62% 91.57% 0.0%
Other Long-Term Liabilities $11.80M $2.200M $4.000M
YoY Change 391.67% -45.0% -20.0%
Total Long-Term Liabilities $23.40M $12.84M $10.70M
YoY Change 36.05% 19.95% -8.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.70M $16.27M $8.100M
Total Long-Term Liabilities $23.40M $12.84M $10.70M
Total Liabilities $46.00M $29.11M $18.70M
YoY Change 71.0% 55.66% -28.08%
SHAREHOLDERS EQUITY
Retained Earnings -$252.6M
YoY Change
Common Stock $53.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $173.9M $51.83M $55.21M
YoY Change
Total Liabilities & Shareholders Equity $220.0M $83.16M $74.00M
YoY Change 202.61% 12.37% 50.41%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$16.78M -$19.65M -$9.645M
YoY Change 57.08% 103.77% 14.71%
Depreciation, Depletion And Amortization $310.0K $280.0K $230.0K
YoY Change 29.17% 21.74% 0.0%
Cash From Operating Activities -$3.560M -$11.52M -$8.870M
YoY Change -63.56% 29.88% 18.11%
INVESTING ACTIVITIES
Capital Expenditures -$730.0K -$280.0K -$410.0K
YoY Change 102.78% -31.71% 105.0%
Acquisitions
YoY Change
Other Investing Activities $14.00M $14.00M $1.750M
YoY Change 0.0% 700.0% -70.83%
Cash From Investing Activities $13.27M $13.72M $1.340M
YoY Change -2.71% 923.88% -76.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 137.4M 1.150M -2.010M
YoY Change 1555.06% -157.21% 5.79%
NET CHANGE
Cash From Operating Activities -3.560M -11.52M -8.870M
Cash From Investing Activities 13.27M 13.72M 1.340M
Cash From Financing Activities 137.4M 1.150M -2.010M
Net Change In Cash 147.1M 3.350M -9.540M
YoY Change 1108.55% -135.12% 163.54%
FREE CASH FLOW
Cash From Operating Activities -$3.560M -$11.52M -$8.870M
Capital Expenditures -$730.0K -$280.0K -$410.0K
Free Cash Flow -$2.830M -$11.24M -$8.460M
YoY Change -69.93% 32.86% 15.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Operating Expenses
OperatingExpenses
21594000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33659000
CY2017Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15893000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7420000
CY2018Q2 us-gaap Assets
Assets
83155000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3510000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8376000
CY2018Q2 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
600000
CY2018Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1776000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2105000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
724000
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
360000
CY2018Q2 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
400000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53388420
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1027000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1026000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2053000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2053000
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Operating Income Loss
OperatingIncomeLoss
-19541000
us-gaap Investment Income Interest
InvestmentIncomeInterest
707000
us-gaap Investment Income Interest
InvestmentIncomeInterest
248000
us-gaap Interest Expense
InterestExpense
837000
us-gaap Interest Expense
InterestExpense
478000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-130000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-230000
us-gaap Net Income Loss
NetIncomeLoss
-33789000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52947926
us-gaap Profit Loss
ProfitLoss
-33789000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
567000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2867000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
38000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
43000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28292000
dei Entity Registrant Name
EntityRegistrantName
FATE THERAPEUTICS INC
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
12000
dei Trading Symbol
TradingSymbol
FATE
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3816000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16816000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52648601
dei Entity Central Index Key
EntityCentralIndexKey
0001434316
dei Amendment Flag
AmendmentFlag
false
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36162000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88952000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2015000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1647000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2018Q2 us-gaap Assets Current
AssetsCurrent
80034000
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53419189
CY2018Q2 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
41857000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
102596000
CY2017Q4 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
11997000
dei Document Type
DocumentType
10-Q
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218798000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
77189000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
227000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2894000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24000
CY2017Q4 us-gaap Assets
Assets
105292000
CY2018Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1462000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
175000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
53000
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
304371000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252587000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83155000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105292000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11049000
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12835000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
51825000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1678000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7254000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2011000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16273000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53388420
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52648601
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1347000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14808000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
53000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
295934000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-19656000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2017Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-9650000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53130518
CY2017Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41406367
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
122000
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2550000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41397398
us-gaap Profit Loss
ProfitLoss
-19771000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
437000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1840000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24074000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16327000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
462000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
566000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30122000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
20632000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-19809000
us-gaap Net Income Loss
NetIncomeLoss
-19771000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-12000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-38000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33801000
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
376000
fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
6100000
CY2017Q2 fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
6100000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5701000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7927000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2669000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9570000
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
137000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
10596000
us-gaap Operating Expenses
OperatingExpenses
35712000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19605000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20300000
us-gaap Straight Line Rent
StraightLineRent
-548000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1053000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1053000
fate Common Stock Issued For License Agreement
CommonStockIssuedForLicenseAgreement
4845000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
336000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
212000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
14000
us-gaap Paid In Kind Interest
PaidInKindInterest
185000
us-gaap Paid In Kind Interest
PaidInKindInterest
138000
us-gaap Straight Line Rent
StraightLineRent
-71000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-364000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2743000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1141000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
55660000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
39971000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
26000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
3500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37037000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
781000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
66000
fate Proceeds From Cirm Award
ProceedsFromCIRMAward
1000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4055000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1511000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4182000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52685000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-57546000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
89074000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88731000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36389000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31185000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (GAAP). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p></div>
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36389000
CY2018Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
21600000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
21600000
CY2017Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20300000
CY2018Q2 fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
7400000
fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
7400000
fate Period To Treat Award As Grant If Award Not Treated As Loan
PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan
P10Y
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
41872000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
12000000
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
41857000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
11997000
CY2018Q2 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2017Q2 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2018Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2017Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2018Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1324000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1761000
CY2018Q2 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
4068000
CY2017Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
3323000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2984000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2170000
CY2018Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2018Q2 fate Debt Instrument Discount Non Current
DebtInstrumentDiscountNonCurrent
81000
CY2017Q4 fate Debt Instrument Discount Non Current
DebtInstrumentDiscountNonCurrent
192000
CY2018Q2 fate Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts
LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts
14919000
CY2017Q4 fate Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts
LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts
14808000
CY2018Q2 fate Long Term Debt Gross Current
LongTermDebtGrossCurrent
2084000
CY2018Q2 fate Debt Instrument Discount Current
DebtInstrumentDiscountCurrent
73000
CY2018Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
200000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1485000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
973000

Files In Submission

Name View Source Status
0001564590-18-019456-index-headers.html Edgar Link pending
0001564590-18-019456-index.html Edgar Link pending
0001564590-18-019456.txt Edgar Link pending
0001564590-18-019456-xbrl.zip Edgar Link pending
fate-10q_20180630.htm Edgar Link pending
fate-20180630.xml Edgar Link completed
fate-20180630.xsd Edgar Link pending
fate-20180630_cal.xml Edgar Link unprocessable
fate-20180630_def.xml Edgar Link unprocessable
fate-20180630_lab.xml Edgar Link unprocessable
fate-20180630_pre.xml Edgar Link unprocessable
fate-ex101_80.htm Edgar Link pending
fate-ex102_223.htm Edgar Link pending
fate-ex311_6.htm Edgar Link pending
fate-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gebp5rm3spaf000001.jpg Edgar Link pending
gebp5rm3spaf000013.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending